Diabetes mellitus complicated with heart failure
Conditions
Interventions
Group B (Recombinant human brain natriuretic peptide treatment for 3 days):NA
Group A (Recombinant human brain natriuretic peptide treatment for 5 days:NA
Sponsors
Second Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. Meets the diagnostic criteria for acute heart failure as outlined in the "2024 Guidelines for the Diagnosis and Treatment of Heart Failure in China" (presence of structural or functional cardiac abnormalities, symptoms of dyspnea at rest or with mild exertion, NT-proBNP levels >450 ng/L for patients under 50 years old, >900 ng/L for those aged 50-75, and >1800 ng/L for those over 75, including cases of new-onset acute heart failure and acute exacerbation of chronic heart failure); 3. Meets the diagnostic criteria for diabetes as outlined in the "Guidelines for the Prevention and Treatment of Diabetes in China (2024 Edition)" (typical diabetes symptoms, random blood glucose >=11.1 mmol/L, or fasting blood glucose >=7.0 mmol/L, or 2-hour blood glucose after OGTT >=11.1 mmol/L, or HbA1c >=6.5%); 4. The patient or their legal guardian agrees to participate in the trial and signs the informed consent form;
Exclusion criteria
Exclusion criteria: 1. During screening, patients who meet the diagnosis of cardiogenic shock include, but are not limited to, those with the following symptoms: (1) persistent hypotension (mean arterial pressure less than 60mmHg, or systolic blood pressure less than 90mmHg); (2) signs of shock and tissue hypoperfusion, such as altered consciousness, skin cyanosis, cold limbs, oliguria or anuria, etc; 2. Patients who are judged by researchers as unsuitable for vasodilator drugs, such as those with severe valvular stenosis, restrictive or obstructive cardiomyopathy, restrictive pericarditis, cardiac tamponade, or other conditions dependent on cardiac output for venous return, or those suspected of having low cardiac filling pressure; 3. Heart failure caused by acute myocardial infarction; 4. Women who are pregnant or breastfeeding; 5. Individuals known or suspected to be allergic to the test product or its contained ingredients; 6. Any other conditions that researchers believe may pose risks to patients;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| CysC;BDNF;HIF-1a; | — |
Countries
China
Contacts
Public ContactWenkai He
Second Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed